Ifosfamide neurotoxicity: An atypical presentation with psychiatric manifestations

Pediatric Blood and Cancer

Volumn 47, Issue 1, 2006, Pages 100-102

  Kerdudo, C ^a   Orbach, D ^a   Sarradet, J L ^b   Doz, F ^a  

^a INSTITUT CURIE   (France)

^b Hopital Esquirol   (France)

Author keywords

Adolescent; Ifosfamide; Neurologic toxicity; Psychiatric manifestation

Indexed keywords

ALIZAPRIDE; ANTIEMETIC AGENT; CLORAZEPATE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; IFOSFAMIDE; METHYLENE BLUE; ONDANSETRON; VINCRISTINE;

ACUTE BRAIN DISEASE; ADOLESCENT; ANXIETY DISORDER; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CEREBELLUM DISEASE; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CRANIAL NERVE PARALYSIS; DROWSINESS; HUMAN; HYPOMANIA; INSOMNIA; LOGORRHEA; MALE; MENTAL DISEASE; NEUROTOXICITY; PRIORITY JOURNAL; RESTLESSNESS; RISK FACTOR; SEIZURE; SPEECH DISORDER; SYMPTOM; SYNOVIAL SARCOMA; URINE INCONTINENCE;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BIPOLAR DISORDER; HUMANS; IFOSFAMIDE; MALE; NEUROTOXICITY SYNDROMES;

EID: 33646885081     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20665     Document Type: Article

References (27)

1. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 1998;34:1050-1062.
2. Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 1986;4:1253-1261.
3. Miller LJ, Eaton VE. Ifosfamide-induced neurotoxicity: A case report and review of the literature. Ann Pharmacother 1992;26: 183-187.
4. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362.
5. Donaldson SS, Draper GJ, Flamant F, et al. Topography of childhood tumors: Pediatric coding system. Pediatr Hematol Oncol 1986;3:249-258.
6. Chastagner P, Sommelet-Olive D, Kalifa C, et al. Phase II study of ifosfamide in childhood brain tumors: A report by the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 1993;21:49-53.
7. Fouladi M, Baruchel S, Chan H, et al. Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas. Childs Nerv Syst 1998;14:590-595.
8. Anderson NR, Tandon DS. Ifosfamide extrapyramidal neurotoxicity. Cancer 1991;68:72-75.
9. Gieron MA, Barak LS, Estrada J. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J Neurooncol 1988;6:29-30.
10. Pratt CB, Goren MP, Meyer WH, et al. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 1990;8:1399-1401.
11. Lewis LD, Meanwell CA. Ifosfamide pharmacokinetics and neurotoxicity. Lancet 1990;335:175-176.
12. Salloum E, Flamant F, Ghosn M, et al. Irreversible encephalopathy with ifosfamide/mesna. J Clin Oncol 1987;5:1303-1304.
13. Verdeguer A, Castel V, Esquembre C, et al. Fatal encephalopathy with ifosfamide/mesna. Pediatr Hematol Oncol 1989;6:383-385.
14. Comandone A, Liboni W, Picci P, et al. Two episodes of ifosfamide-related neurotoxicity in the same patient following different schedules and doses of the drug. A case report. Tumori 2000;86: 483-486.
15. Antunes NL. The spectrum of neurologic disease in children with systemic cancer. Pediatr Neurol 2001;25:227-235.
16. Vassal G. [Pharmacologic bases of chemotherapy of brain tumors in children]. Bull Cancer 1990;77:699-713.
17. Byrd RL, Rohrbaugh TM, Raney RB Jr, et al. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer 1981;47:37-40.
18. Akman SA, Block JB. Neurologic complications of systemic cancer. Prim Care 1984;11:597-623.
19. Donegan S. Novel treatment for the management of ifosfamide neurotoxicity: Rationale for the use of methylene blue. J Oncol Pharm Practice 2001;6:153-165.
20. Brain EG, Yu LJ, Gustafsson K, et al. Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation in vivo. Br J Cancer 1998;77:1768-1776.
21. Gentile DM, Tomlinson ES, Maggs JL, et al. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996;277: 105-112.
22. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
23. Canpolat C, Pearson P, Robertson R, et al. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: Renal, hematologic, and neurologic observations. Med Pediatr Oncol 1996;26:36-47.
24. Simonian NA, Gilliam FG, Chiappa KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology 1993;43:2700-2702.
25. Dourthe LM, Coutant G, Desrame J, et al. [Ifosfamide-related encephalopathy. Report of two cases]. Rev Med Interne 1999;20: 264-266.
26. Kasper B, Harter C, Meissner J, et al. Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? Support Care Cancer 2004;12:205-207.
27. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996;50:249-252.